Allianz SE Has $1.34 Million Position in Boston Scientific Corporation $BSX

Allianz SE raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 397.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,770 shares of the medical equipment provider’s stock after purchasing an additional 11,000 shares during the quarter. Allianz SE’s holdings in Boston Scientific were worth $1,344,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Generali Investments Management Co LLC grew its holdings in shares of Boston Scientific by 5.3% during the third quarter. Generali Investments Management Co LLC now owns 42,193 shares of the medical equipment provider’s stock valued at $4,119,000 after buying an additional 2,135 shares during the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co lifted its position in Boston Scientific by 12.7% in the 3rd quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 9,765 shares of the medical equipment provider’s stock valued at $953,000 after acquiring an additional 1,100 shares in the last quarter. Andra AP fonden boosted its stake in Boston Scientific by 5,000.0% during the 3rd quarter. Andra AP fonden now owns 19,278 shares of the medical equipment provider’s stock valued at $1,882,000 after purchasing an additional 18,900 shares during the last quarter. Sumitomo Mitsui Financial Group Inc. increased its holdings in Boston Scientific by 12.9% during the 3rd quarter. Sumitomo Mitsui Financial Group Inc. now owns 265,781 shares of the medical equipment provider’s stock worth $25,948,000 after purchasing an additional 30,300 shares in the last quarter. Finally, Telligent Fund LP purchased a new stake in shares of Boston Scientific in the third quarter worth approximately $1,172,000. 89.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on BSX shares. Robert W. Baird cut their target price on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. UBS Group cut their price objective on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, February 5th. Stifel Nicolaus reduced their target price on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. Mizuho dropped their price target on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $108.36.

Boston Scientific Price Performance

BSX opened at $76.68 on Friday. Boston Scientific Corporation has a fifty-two week low of $72.69 and a fifty-two week high of $109.50. The firm has a 50-day moving average of $87.31 and a 200 day moving average of $95.60. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The firm has a market cap of $113.78 billion, a P/E ratio of 39.52, a PEG ratio of 1.06 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the previous year, the company earned $0.70 earnings per share. The company’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Street sentiment and recent analyst commentary lean favorable after the company’s quarterly results and guidance; the board added Cathy Smith and Christophe Weber, which investors view as governance/strategic strengthening. What Does the Street Think About Boston Scientific Corporation (BSX)?
• Positive Sentiment: Boston Scientific arranged multiple credit facilities totaling roughly $11 billion, boosting liquidity and providing financial flexibility for M&A, R&D, or share-repurchase plans — a constructive sign for risk management and capital strategy. Boston Scientific enters into multiple credit facilities totaling $11B
• Positive Sentiment: Management promoted an internal candidate to president of Vascular Therapies, signaling leadership continuity and succession depth in a key growth division. Boston Scientific promotes new president of Vascular Therapies from within
• Neutral Sentiment: Market coverage notes BSX is “trending” and trading up relative to the broader market on the session, driven partly by investor interest after earnings — useful for short-term flows but not a fundamental change. Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: Commentary points out BSX has trailed the Dow over recent periods despite analyst optimism — flags for investors focused on relative performance and timing for rotation into healthcare. Is Boston Scientific Stock Underperforming the Dow?
• Negative Sentiment: FDA-linked reporting: Boston Scientific halted use of certain AXIOS stent delivery devices after deployment issues associated with 167 injuries and three deaths — a material product-safety concern that can affect revenue, litigation exposure and reputation in the short-to-medium term. Boston Scientific Halts Use Of Select Stent Delivery Devices After Patient Deaths
• Negative Sentiment: An investor law firm (Pomerantz) has opened an investigation into claims on behalf of BSX investors, increasing legal risk and potential headline volatility. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation – BSX

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This represents a 42.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The SEC filing for this sale provides additional information. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.